Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Waiting For EGFR Diagnostic Kit Data As Supplement To Vectibix BLA

Executive Summary

In what could signal a trend for targeted therapies, FDA concluded in its review of Amgen's epidermal growth factor receptor inhibitor Vectibix that the diagnostic test kit used to screen subjects for EGFR expression would need to be submitted as a supplement to the BLA

You may also be interested in...

FDA Offers Possible Reasons For Vectibix Failure To Show Survival Benefit

FDA review documents for Amgen's Vectibix (panitumumab) outline possible factors that may have lead to the epidermal growth factor receptor inhibitor's failure to show an overall survival benefit in a pivotal trial, including the possibility that the trial was not powered to show a modest effect

Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China

Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts